Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 8Carcinoma, Transitional Cell 8Breast Neoplasms 7Lung Neoplasms 6Ovarian Neoplasms 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Testicular Neoplasms 3Stomach Neoplasms 3Sarcoma 3Melanoma 3Fallopian Tube Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Oropharyngeal Neoplasms 2Neoplasms, Unknown Primary 2Mouth Neoplasms 2Lymphoma, Non-Hodgkin 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Teratoma, Testicular 1

Interventions

Taxes 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cervical Adenocarcinoma × Taxes × Genitourinary × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡